Compare Stocks: NTRB, IKT, VNDA, and AMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63 -1.7%	$14.03	$12.96 ▼ $20.90	$287.91M	0.76	80,412 shs	50,664 shs
IKT Inhibikase Therapeutics	$2.30	$2.34	$1.33 ▼ $2.61	$320.93M	0.95	368,808 shs	3.21 million shs
NTRB Nutriband	$8.13 +6.3%	$4.20	$2.80 ▼ $8.63	$98.83M	2.03	72,320 shs	110,092 shs
VNDA Vanda Pharmaceuticals	$5.13 +0.4%	$5.29	$4.27 ▼ $9.94	$310.18M	0.64	664,773 shs	1.66 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	0.00%	-1.23%	-3.06%	-14.97%	-6.64%
IKT Inhibikase Therapeutics	0.00%	-1.71%	-2.13%	+25.68%	+47.44%
NTRB Nutriband	0.00%	+16.81%	+112.83%	+180.34%	+17.49%
VNDA Vanda Pharmaceuticals	0.00%	+0.79%	-4.65%	-11.55%	+16.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63 -1.7%	$14.03	$12.96 ▼ $20.90	$287.91M	0.76	80,412 shs	50,664 shs
IKT Inhibikase Therapeutics	$2.30	$2.34	$1.33 ▼ $2.61	$320.93M	0.95	368,808 shs	3.21 million shs
NTRB Nutriband	$8.13 +6.3%	$4.20	$2.80 ▼ $8.63	$98.83M	2.03	72,320 shs	110,092 shs
VNDA Vanda Pharmaceuticals	$5.13 +0.4%	$5.29	$4.27 ▼ $9.94	$310.18M	0.64	664,773 shs	1.66 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	0.00%	-1.23%	-3.06%	-14.97%	-6.64%
IKT Inhibikase Therapeutics	0.00%	-1.71%	-2.13%	+25.68%	+47.44%
NTRB Nutriband	0.00%	+16.81%	+112.83%	+180.34%	+17.49%
VNDA Vanda Pharmaceuticals	0.00%	+0.79%	-4.65%	-11.55%	+16.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.33	Sell	$13.00	-4.62% Downside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	134.78% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$13.70	167.06% Upside

Current Analyst Ratings Breakdown

Latest NTRB, IKT, VNDA, and AMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/17/2026	AMRN Amarin	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/1/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$213.65M	1.35	$0.36 per share	37.76	$22.07 per share	0.62
IKT Inhibikase Therapeutics	$260K	1,234.39	N/A	N/A	$2.30 per share	1.00
NTRB Nutriband	$2.04M	48.46	N/A	N/A	$0.44 per share	18.48
VNDA Vanda Pharmaceuticals	$216.10M	1.44	N/A	N/A	$5.54 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
NTRB Nutriband	-$8.23M	-$0.53	N/A	N/A	N/A	-430.35%	-109.07%	-95.54%	9/30/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest NTRB, IKT, VNDA, and AMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q2 2027	NTRB Nutriband	N/A	-$0.07	N/A	-$0.07	N/A	$0.44 million
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.67	2.67
IKT Inhibikase Therapeutics	N/A	15.82	15.82
NTRB Nutriband	N/A	4.21	4.02
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
IKT Inhibikase Therapeutics	3.81%
NTRB Nutriband	19.70%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	4.21%
IKT Inhibikase Therapeutics	7.10%
NTRB Nutriband	52.21%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	80	21.12 million	20.23 million	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
NTRB Nutriband	3	12.16 million	5.81 million	Not Optionable
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable

NTRB, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026 | prnewswire.com

BlackRock Inc. Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

September 1, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.32 Million in Vanda Pharmaceuticals Inc. $VNDA

August 31, 2026 | marketbeat.com

Ieq Capital LLC Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

August 26, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA)

August 25, 2026 | finance.yahoo.com

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026 | prnewswire.com

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026 | prnewswire.com

Vanda (VNDA) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

August 11, 2026 | zacks.com

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

August 5, 2026 | tipranks.com

Vanda: Q2 Earnings Snapshot

August 5, 2026 | chron.com

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 5, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo Finance

July 29, 2026 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 29, 2026 | prnewswire.com

Vanda Pharmaceuticals: Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold

July 17, 2026 | seekingalpha.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a ...

July 17, 2026 | uk.finance.yahoo.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

July 16, 2026 | prnewswire.com

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

July 15, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB, IKT, VNDA, and AMRN Company Descriptions

Amarin NASDAQ:AMRN

$13.63 -0.24 (-1.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.63 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inhibikase Therapeutics NASDAQ:IKT

$2.30 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.30 0.00 (-0.22%)

As of 09/18/2026 07:30 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Nutriband NASDAQ:NTRB

$8.13 +0.48 (+6.27%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.28 +0.15 (+1.89%)

As of 09/18/2026 07:37 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.13 +0.02 (+0.39%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.12 -0.01 (-0.19%)

As of 09/18/2026 07:30 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTRB, IKT, VNDA, and AMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTRB, IKT, VNDA, and AMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTRB, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB, IKT, VNDA, and AMRN Company Descriptions

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

Nutriband NASDAQ:NTRB

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTRB, IKT, VNDA, and AMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTRB, IKT, VNDA, and AMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTRB, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB, IKT, VNDA, and AMRN Company Descriptions

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

Nutriband NASDAQ:NTRB

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools